39 citations
,
January 1977 in “Dermatology” The treatment cleared psoriasis in some patients but caused side effects in most.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
5-ARI therapy may help prevent prostate cancer progression.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
March 2026 in “Research Square” 1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
January 2025 in “JAAD International” Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
1 citations
,
March 2016 in “Journal of The American Academy of Dermatology” More research needed to confirm finasteride as standard treatment for FFA.
4 citations
,
January 2015 in “Pharmacology” Serenoa repens may cause early puberty and should be used cautiously in children.
41 citations
,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
8 citations
,
February 2009 in “Current Women's Health Reviews” Testosterone treatment can improve sexual function and bone density in women but may have adverse effects and requires more research on safety and guidelines.
November 2015 in “Clin-Alert” Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
108 citations
,
March 2006 in “Archives of Dermatology” Finasteride with oral contraceptive helps improve hair loss in premenopausal women.
1 citations
,
January 2014 in “ScholarWorks - University of Montana (University of Montana)” Finasteride reduces low-grade prostate cancer but may not be beneficial overall.
August 2022 in “Indonesian Journal of Medical Chemistry and Bioinformatics” Certain herbal compounds might help prevent hair loss in menopausal women by activating Vitamin D receptors.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
203 citations
,
December 1947 in “Annals of Internal Medicine” October 2025 in “Actas Dermo-Sifiliográficas” RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
9 citations
,
April 2019 in “Molecules” Blackcurrant extract may help reduce hair loss by promoting stem cell activity in hair follicles.
March 2023 in “Advances in Clinical and Experimental Medicine” Oral and topical finasteride are effective and safe for treating female hair loss.
3 citations
,
April 2021 in “Journal of Medicinal Chemistry” Finasteride may affect PNMT, causing side effects.
20 citations
,
January 1994 in “Archives of Biochemistry and Biophysics” Minoxidil needs specific structure to block lysyl hydroxylase; exploring alternatives may keep benefits without this effect.
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
24 citations
,
July 1980 in “Journal of Toxicology and Environmental Health” High doses of norethindrone acetate in rats caused various organ changes but didn't significantly increase tumor rates.
48 citations
,
July 2023 in “Pediatric Dermatology” The ALLEGRO phase 2b/3 trial evaluated the efficacy and safety of ritlecitinib, a JAK3/TEC family kinase inhibitor, in 105 adolescents aged 12-17 with alopecia areata and ≥50% scalp hair loss. Over 48 weeks, 25%-50% of patients in the ritlecitinib groups achieved significant hair regrowth (SALT score ≤20), compared to 0% in the placebo group. Additionally, 44%-80% of adolescents reported moderate to great improvement in their condition with ritlecitinib, versus 10%-22% with placebo. Common adverse events included headache, acne, and nasopharyngitis, but no severe adverse events were reported. Overall, ritlecitinib showed promising efficacy and a favorable safety profile for treating alopecia areata in adolescents.
6 citations
,
April 2016 in “PubMed” The review found that women using hair loss drugs like finasteride and dutasteride rarely reported sexual side effects.